https://www.avient.com/sites/default/files/resources/PolyOne%2520Investor%2520Presentation%2520Jefferies%25202013%2520Global%2520Industrial%2520Conference_Posting.pdf
They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual
results to differ materially from those expressed in or implied by the forward-looking statements.
PolyOne’s chief operating decision makers use these financial measures to
monitor and evaluate the ongoing performance of the Company and each
business segment and to allocate resources.
Platform operating income mix percentage 2005Y* 2008Y* 2010Y* 2012Y* 2012PF** H1 2013***
Global Specialty Engineered Materials $ 0.4 $ 17.6 $ 49.7 $ 47.0 $ 47.7 $ 32.5
Global Color, Additives and Inks 4.3 28.1 37.7 66.8 81.6 54.7
Designed Structures & Solutions - - - - 20.9 10.5
Specialty Platform $ 4.7 $ 45.7 $ 87.4 $ 113.8 $ 150.2 $ 97.7
Performance Products and Solutions 75.7 31.3 54.0 74.9 37.4 27.5
Distribution 19.5 28.1 42.0 66.0 66.0 33.1
SunBelt Joint Venture 91.9 28.6 18.9 - - -
Corporate (51.5) (425.1) (27.7) (87.6) (87.9) (37.1)
Operating income (loss) GAAP $ 140.3 $ (291.4) $ 174.6 $ 167.1 $ 165.7 $ 121.2
Less: Corporate operating expense (income) 51.5 425.1 27.7 87.6 87.9 37.1
Operating income excluding Corporate $ 191.8 $ 133.7 $ 202.3 $ 254.7 $ 253.6 $ 158.3
Specialty platform operating mix percentage 2% 34% 43% 45% 60% 62%
* Historical results include the Resin and Specialty Coatings businesses within the Performance Products and Solutions segment.
** Pro Forma results include Spartech and Glasforms acquisitions, Specialty Coatings reclass and exclude the Resin business assets.
*** Restated results to exclude the Resin business and to remove Specialty Coatings from the Performance Products and Solutions segment into
Global Color, Additives and Inks segment.
https://www.avient.com/idea/securing-supplies-medical-plastic-solutions
For the plastics used in these medical applications, this can mean compliance with the relevant chapters of the International Organization for Standardization (ISO), the United States Pharmacopeia Class VI (USP VI) the European Pharmacopeia (EP 3.1), and the International Conference on Harmonization (ICH Q3D) standards and guidelines.